Thirty-six neonates in whom hypothyroidism was diagnosed after thyroid stimulating hormone screening were reassessed at 1 year. All had grown satisfactorily and the mental development scores were normal in all except two. Treatment was withdrawn in 32 and persistent hypothyroidism was confirmed in 31 cases. Thyroid stimulating hormone concentrations were raised in onethird of cases before the withdrawal of treatment and this was associated with generally lower concentrations of serum thyroxine (T4) and smaller doses of L-thyroxine than in those cases with normal concentrations of thyroid stimulating hormone.
Introduction
The widespread introduction of neonatal hypothyroid screening in many parts of Western Europe and North America has shown a higher incidence of congenital hypothyroidism (about one in 4000-4500)1 than was suspected previously from retrospective studies (about one in 6500-7000).' One explanation for this discrepancy might lie in the inclusion of cases is usually advised to confirm the diagnosis of hypothyroidism. We re-evaluated 36 cases at 1 year and report our findings.
Patients and methods
Primary congenital hypothyroidism was diagnosed in 36 neonates screened for raised concentrations of thyroid stimulating hormone from September 1978 to September 1980. The programme covered the North-east and North-west Thames Health Regions and details of the screening procedures and of the results have already been published.5 6At the time of diagnosis, investigations included measurement of serum thyroxine (T4), thyroid stimulating hormone, triiodothyronine (T3), reverse triiodothyronine, thyroxine-binding globulin, and thyroglobulin; estimation of bone age at the left knee and foot; and, in most cases, a 123I thyroid scan. Detailed results of these investigations are available elsewhere.5 7 The mean age of starting treatment was 30 6 ± SD 8-6 days (range 17-57 days). In most cases, day-to-day care was supervised by local paediatricians.
The children were recalled for re-evaluation and developmental assessment at the age of 1 year. At the first visit, while still being treated with L-thyroxine, they were weighed, length and head circumference were measured, and a Griffiths developmental assessment performed. Bone age was estimated and blood taken for estimation of serum T4, thyroid stimulating hormone, T3, reverse T3, thyroxine-binding globulin and thyroglobulin. A "T3 withdrawal test" was then performed as follows: triiodothyronine (10 isg twice daily) was substituted for thyroxine for three weeks then treatment was stopped completely for one week and a further blood sample taken. Thyroxine was restarted while awaiting test results. The purpose of the T3 withdrawal test was to use the short half life of triiodothyronine (two days) to minimise the period of treatment withdrawal.
Results
Thirty-six infants (11 boys and 25 girls) were seen for developmental assessment. Their mean ages were 1-06 ±0 07 years for the boys and 1-03 +0-06 years for the girls. Formal T3 withdrawal tests were performed on 32; parental consent was refused in one case who was athyrotic on the scan, three others had clinical or biochemical evidence of persistent hypothyroidism (a low T4 and high thyroid stimulating hormone) at the time of the first visit. Nine other cases who had been diagnosed during the first two years of screening were not seen; two had been lost to follow-up, two were unable to attend, and in five cases the local paediatricians felt-that reassessment was unnecessary. All cases with mild hypothyroidism at initial diagnosis were reassessed. Table I gives growth data. The mean heights and weights were just above the 50th centile for the boys and just below the 50th centile for the girls at the mean age of assessment. None had heights or weights below the 3rd centile for age. The mean head circumferences, however, were larger than expected. The mean bone age at the wrist was 1-02±0-28 years.8 Thus physicial growth was generally satisfactory. One child showed a pattern of accelerating growth and was recognised as having cerebral gigantism from the facial features, growth pattem, advanced bone age, and characteristic findings on CT scan.9 The mean quotient of results of the Griffiths assessment was 104-2±7-9. Two children had Griffiths scores of less than 90; one was the child with cerebral gigantism and athyrotic hypothyroidism already mentioned (quotient 89) and the other a child who was undertreated at the time (quotient 81). There was no significant difference between the Griffiths quotients of the athyrotic cases and those with some thyroid tissue present on the initial scan. The mean scores for the subscales were as follows: scale A (locomotor) 106-8±11-9; B (personal/social) 101-3±6 9; C (hearing and speech) 1009 ± 10 1; D (eye/hand) 105-0±8-8; E (performance) 104-6±12 2. The differences between subscales were not significant. concentrations of thyroid stimulating hormone (>10 mU/l) before treatment withdrawal, though only three of these had T4 values below 90 nmol/l (6-9 pg/100 ml). The mean T4 value for these children was lower, however (mean 100-9 ±20 nmol/l (7-8 ±1-5 jsg/100 ml)) than that for children without persistently raised concentrations of thyroid stimulating hormone (mean 144 ±40-8 nmol/l (11-2 ±3-2 Htg/100 ml); t =4-01, p>0-001). In addition, the mean dose of thyroxine was lower in the children with persistently raised concentrations of thyroid stimulating hormone (mean 35-2±12-2 ,ug/day) than in the others (mean 53-8±15 tg/day; t==377, p>0001). 
